Yuflyma Kit
NDC Package 72606-024-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Yuflyma (adalimumab-aaty) kits is none. This formulation utilizes a kit delivery system. Marketed by Celltrion Usa, Inc., this product is identified by NDC 72606-024 and is authorized under FDA application BLA761219.

Identification & Billing

NDC Package Code
72606-024-01
Package Description
2 KIT in 1 CARTON / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .2 mL in 1 SYRINGE * 1 mL in 1 PACKET
Product Code
72606-024
11-Digit Billing Format
72606002401
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Yuflyma
Non-Proprietary Name
Adalimumab-aaty
Dosage Form
Kit - A packaged collection of related material.
Usage Information
None.

Regulatory & Marketing

Labeler Name
Celltrion Usa, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761219
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
09-29-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Q5141
Source: PDAC
INJECTION, ADALIMUMAB-AATY, BIOSIMILAR, 1 MG
HCPCS Dosage 1 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72606-024-01 identifies a specific commercial package of 2 kit in 1 carton / 1 kit in 1 kit * 1 syringe in 1 tray / .2 ml in 1 syringe * 1 ml in 1 packet of Yuflyma, a human prescription drug labeled by Celltrion Usa, Inc.. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Celltrion Usa, Inc. on September 29, 2023. The current certification is valid through December 31, 2026.

How is this Celltrion Usa, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72606002401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72606-024-01
11-Digit CMS (5-4-2)
72606-0024-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.